Rutgers scientists form immuno-oncology biotech to develop pipeline of TAM inhibitors
There are thousands of immuno-oncology therapies in the global pipeline, and researchers from Rutgers are adding to that tally, with a family of compounds that could potentially be used in tandem with established checkpoint inhibitors for a plethora of cancers, as part of a newly formed biotech named TamRx.
Funded by BioMotiv, the for-profit accelerator of The Harrington Project, TamRx’s technology inhibits TAM (Tyro3, Axl, and Mertk), a family of receptor tyrosine kinases implicated in a wide spectrum of human cancers. Elevated TAM signaling is heavily associated with cancer progression, metastasis, and resistance to targeted therapies. TamRx’s inhibitors are designed to thwart tumor growth and metastasis and to stimulate the immune system to enhance its an anti-tumor response, the company said on Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.